Last reviewed · How we verify
bimatoprost ophthalmic solution 0.03%
At a glance
| Generic name | bimatoprost ophthalmic solution 0.03% |
|---|---|
| Also known as | LATISSE®, Lumigan®, LUMIGAN® |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study
- Topical Bimatoprost for Chemical Blepharoplasty (EARLY_PHASE1)
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose (PHASE4)
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost ophthalmic solution 0.03% CI brief — competitive landscape report
- bimatoprost ophthalmic solution 0.03% updates RSS · CI watch RSS
- Allergan portfolio CI